Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Biotechnology

Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

Pharma

Pharma’s new justification for high drug prices, and other takeaways from #BI02017

By Rebecca Robbins and Damian Garde

advertisement

Biotech

This investor predicted the big biotech stock rally. And he thinks it has legs

By Adam Feuerstein

advertisement

Biotech

David Cameron: Biotech execs can still count on doing business in a post-Brexit U.K.

By Rebecca Robbins

Biotech

Biotech stocks are soaring. Here are four reasons why

By Adam Feuerstein

Biotech

Meet the scientist who keeps J&J up with the Joneses

By Damian Garde

Biotech

Camille Samuels: Favoring ‘new markets for unmet needs’

By Meghana Keshavan

advertisement

First Opinion

Bedside drug production will truly enable personalized medicine

By Huub Schellekens

advertisement

Biotech

Biotech R&D costs are outpacing revenues, but funding is still strong, report says

By Meghana Keshavan

In the Lab

Are drug makers overlooking the next big category of sleep drugs?

By Rebecca Robbins

Biotech

China rises as a biotech powerhouse, developing drugs to treat the world

By Damian Garde

Biotech

How John Flannery recast GE Healthcare and its biologics business

By Karen Weintraub

In the Lab

FBI raids offices of lab that pays doctors to promote genetic tests

By Charles Piller

Biotech

Vertex goes all-in on its effort to conquer cystic fibrosis

By Robert Weisman

Health

A first: All respond to CAR-T therapy in a blood cancer study

By Associated Press

Biotech

Meet the biotech company trying to shake up how the FDA thinks about cancer drugs

By Damian Garde

Biotech

Three key stories we’re watching for at ASCO

By Damian Garde

First Opinion

Biomedical innovation depends on immigrants’ contributions

By Johannes Fruehauf

First Opinion

This map will help biologists learn more about the human body than ever before

By Aviv Regev and Sarah Teichmann

Business

CRISPR stocks sank on news the gene editing tool can veer off target. But that’s hardly news

By Sharon Begley

Biotech

Moderna’s top attorney quits during an all-important legal dispute

By Damian Garde

Pharma

‘Our health care system values potential,’ drug-pricing report concludes

By Meghana Keshavan

Biotech

Bain bowls into biotech with $720 million and an eye for ‘fallen angels’

By Damian Garde

Business

Robert Califf to join Google life sciences spinoff Verily

By Charles Piller

Biotech

Why nabbing former FDA commissioner Robert Califf would be a win for Verily

By Charles Piller

Heavyweights

Henri Termeer, biotech leader who built Genzyme into an industry giant, dies at 71

By Bryan Marquard and Robert Weisman — Boston Globe

Business

Soon-Shiong rails against ‘false reporting’ as he announces lackluster sales

By Rebecca Robbins

Biotech

Fungus that once stonewashed jeans now offers promise in biotech

By Karen Weintraub

Politics

Trump wants faster FDA action, but 1 in 3 drugs have safety issues after approval

By Sydney Lupkin — Kaiser Health News

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT